



International Journal of
Medicinal Chemistry & Analysis

www.ijmca.com

e ISSN 2249 - 7587

Print ISSN 2249 - 7595

SIMULTANEOUS ESTIMATION OF LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE DRUGS IN SOLID DOSAGE FORM BY RP-HPLC

***G. Aruna, M. Chanukya, V. Reddy Mohan**

*Department of Pharmaceutical Analysis, Krishna Teja Pharmacy College,
Chadalawada Nagar, Tirupati, Andhra Pradesh – 517 501, INDIA.

ABSTRACT

A simple, specific, accurate and precise RP HPLC method has been developed for the simultaneous determination of Losartan Potassium (LOS) and Hydrochlorothiazide (HCTZ) from combined dosage form by reverse phase C18 column (Prontosil; CN (250mm x 4.6mm) 5 μ). The sample was analysed using Triethylamine: Acetonitrile: Methanol in the ratio of 30:30:40 (pH adjusted to 7.0 with phosphoric acid) as a mobile phase at a flow rate of 1.0ml/min and detection at 270nm. The retention time for Losartan potassium (LOS) and Hydrochlorothiazide (HCTZ) was found to be 11.869 min and 7.893 min respectively. The stability assay was performed for this combination and was validated for accuracy, precision, linearity, specificity and sensitivity in accordance with ICH guidelines. Validation revealed the method is specific, rapid, accurate, precise, reliable, and reproducible. Calibration plots were linear over the 70%-130% concentration ranges for both the drugs of LOS and HCTZ respectively, and recoveries from combined dosage form were between 98 and 102%.

Keywords: Losartan Potassium, Hydrochlorothiazide, RP-HPLC, Estimation.

INTRODUCTION

Losartan Potassium [1] is an Angiotensin II receptor Antagonist used as an anti-hypertensive. Hydrochlorothiazide [2] is a Loop Diuretics used as an anti hypertensive by reducing symptomatic oedema. This reduces the volume of the blood, decreasing blood return to the heart and thus cardiac output and, by other mechanisms, is believed to lower peripheral vascular resistance. Literature survey reveals the availability of several methods for estimation of both Losartan Potassium [3-8] and Hydrochlorothiazide [9-11] includes UV, HPLC as alone or in combination with other drugs. Method has been reported for the estimation of Losartan Potassium and Hydrochlorothiazide in combined dosage form. Present work emphasizes on the stability testing of Losartan Potassium and Hydrochlorothiazide in their combined dosage form by RP-HPLC. Literature survey reveals that there is method developed for the combination Losartan Potassium and Hydrochlorothiazide [8].

Experimental

A High Performance Liquid Chromatograph system, the purity determination performed on a stainless steel column 250mm long, 4.6mm internal diameter filled with Octadecyl silane chemically bonded to porous silica particles of 5 μ m diameter reverse phase C18 column (Zorbax CN (250mm x 4.6mm) 5 μ). Optimized chromatographic conditions are listed in Table 1.

Materials and Chemicals

Pure samples of Losartan Potassium and Hydrochlorothiazide were obtained from Unichem Pvt.Ltd. for the estimation of Losartan Potassium and Hydrochlorothiazide in commercial formulations. HPLC grade phosphoric acid, Acetonitrile and Methanol were procured from institute and of Rankem Ltd. High pure water prepared by using Millipore Milli Q plus purification system.

Preparation of Standard Stock Solution:

Solution A: Weigh accurately about 25 mg of Losartan Potassium working standard in a 50 ml volumetric flask. Dissolve and dilute up to mark with diluent (500ppm).

Solution B: Weigh accurately about 25 mg of Hydrochlorothiazide working standard in a 100 ml volumetric flask. Dissolve and dilute up to mark with diluent (250ppm).

Mixed Standard Preparation

Pipette out 10 ml of solution A and 5 ml of solution B into a 100 ml volumetric flask. Make the volume up to mark with diluent (50ppm of Losartan potassium and 12.5ppm of Hydrochlorothiazide).

Preparation of test sample

Sample Stock Preparation

Weigh and transfer 5 tablets in a 250 ml volumetric flask. Add about 150ml of diluent sonicate till the tablet get disperse completely shake and sonicate extra 10min after tablet get disperse with vigorous shaking cool and make up the volume with diluent.

Sample Preparation

Take 5ml of the sample stock solution in 200ml flask and make up the volume with diluent. Filter the solution through 0.45 nylon membrane filter paper (50ppm of Losartan potassium and 12.5ppm of Hydrochlorothiazide).

Validation of the Method [12,13]

The method was validated in terms of linearity, accuracy, precision and specificity of the sample applications. The linearity of the method was investigated by serially diluting the stock solutions of Losartan Potassium, Hydrochlorothiazide and measured the absorbance at 270nm. Calibration curves were constructed by plotting the area against the concentration. Losartan Potassium shows the linearity in the concentration range from 35-65ppm with correlation coefficient of 0.999 and Hydrochlorothiazide shows the linearity in the concentration range from 8.75-16.75ppm with correlation coefficient of 0.999. Recovery studies were carried out to study the accuracy of the proposed method and ascertained by standard addition method. A known amount of drug was added to reanalyzed tablet powder, at three level and the percentage recoveries were calculated. Precision was found to be lower than 1%. Ruggedness of the proposed method was determined by analysis of aliquots from homogenous slot by different analysts using similar operational and environmental conditions.

Results and Discussion

Estimation

A RP-HPLC method was developed for the simultaneous estimation of Losartan Potassium and Hydrochlorothiazide in combined dosage forms, which can be conveniently employed for routine quality control in pharmaceutical dosage forms. The chromatographic conditions were optimized in order to provide a good performance of the assay. The standard and sample solutions were prepared and chromatograms were recorded.

The peak area ratios of standard and sample solutions were calculated. The assay procedure was repeated for 6 times and mean peak area, mean peak area ratio, mean weight of standard drugs, mean weight of sample taken for assay were calculated. The percentages of individual drugs found in formulations, mean and relative standard deviations in formulation were calculated. The result of analysis shows that the amount of drugs present in the formulation has a very good correlation with the label claim of the formulation.

Validation of the method

System Precision

The precision of the system was determined by injecting standard solution in HPLC. A known quantity of the pure drug was added to make Concentration (50ppm of Losartan potassium and 12.5ppm of Hydrochlorothiazide). The System Precision studies were carried out injecting standard solution 10 times in HPLC system (Table-2).

Method Precision

The precision of the system was determined by injecting sample solution in HPLC. A known quantity of the sample was added to make Concentration (50ppm of Losartan potassium and 12.5ppm of Hydrochlorothiazide). The Method Precision studies were carried out injecting Sample solution 6 trials in HPLC system. Calculate percentage Assay value of 6 trials (Table-3).

Accuracy of the Method

The accuracy of the method was determined by recovery experiments. A known quantity of the pure drug was added to the pre-analyzed sample formulation at 70%-130% levels. The recovery studies were carried out 6 times of each level and the percentage recovery and mean of the percentage recovery were calculated and given in Table 2. From the data obtained, it was observed that the recoveries of standard drugs were found to be accurate and within the specified limits (Table-4).

The precision of the method was determined by studying repeatability and reproducibility. The area of drug peaks and percentage relative standard deviation were calculated. The results revealed that the developed method was found to be reproducible in nature.

The standard drug solutions in varying concentrations ranging from 70% to 130 % of the targeted level of the assay concentration were examined by the assay procedure. Losartan Potassium and Hydrochlorothiazide were found to be linear in the range of 35 to 65ppm and 8.75-16.25ppm respectively.

The slope, intercept and correlation coefficient values were also calculated. The correlation coefficient of Losartan Potassium and Hydrochlorothiazide were found to be 0.999 and 0.999 respectively. The calibration curves were plotted as peak area Vs concentration of the standard solutions. The calibration graph shows that linear response was obtained over the range of concentrations used in the assay procedure. These data demonstrates that the methods have adequate sensitivity to the concentration of the analytes. The range demonstrates that the method is linear outside the limits of expected use. The additional peaks were observed in the chromatogram of the formulation,

which may be due to excipients present in the formulation. These peaks do not interfere with the standard peaks, which clearly confirm the assay method was found to be highly specific.

The system suitability studies were performed for the standard solutions and were presented in Table 3. The values obtained demonstrated the suitability of the system for the analysis of the above drug combination.

From the experimental data (Table- 5) results and parameters it was concluded that the developed RP-HPLC method has the following advantages.

- Ø The standard and sample preparation requires less time.
- Ø No tedious extraction procedure was involved in the analytical process.
- Ø Suitable for the analysis of raw materials. Run time required for recording chromatograms were less than 15 times.

Table 1: Optimized Chromatographic conditions

Parameter	Optimized condition
Instrument	Waters HPLC/Empower software/PDA detector
Column	Zorbax CN (250mm x 4.6mm) 5 μ
Mobile phase*	Triethylamine: Acetonitrile: Methanol in the ratio of 30:30:40(pH adjusted to 7.0 with phosphoric acid)
Flow rate	1.0ml/min
Detection	270nm
Injection volume	20 μ l
Temperature	Ambient

*Filtered through a 0.45 μ membrane filter (Millipore), degassed and sonicated

Table 2. System Precision

Assay No.	Standard peak area For losartan 50ppm	Standard peak area For hctz 12.5ppm
1	847410	966274
2	852145	973023
3	840808	960635
4	860665	984912
5	847918	969477
6	847101	968552
7	860642	969450
8	847938	969520
9	860660	969850
10	860580	984850
Mean	852587	971654
% RSD	0.9	0.8

TABLE 3. SYSTEM PRECISION


Trial No.	Losartan Potassium assay (%)	Hctz assay (%)
1	100.5	99.8
2	100.8	100.2
3	100.3	99.2
4	100.8	99.8
5	100.7	100.1
6	100.5	100.0
Mean	100.7	100.2
% RSD	0.4	0.4

Table 4. Analysis of Formulation and Recovery studies

Assay No.	Mean peak area For losartan 50ppm	Losartan Potassium assay (%)	Mean peak area For hctz 12.5ppm	Hctz assay (%)
1	847410	100.5	966274	99.8
2	852145	100.9	973023	100.5
3	840808	100.3	960635	99.2
4	860665	100.8	984912	99.7
5	847918	100.7	969477	100.1
6	847101	101.0	968552	100.0
Mean	849341.02	100.7	970478.8	100.2
% RSD	0.78	0.4	0.84	0.4

Table 5. System Suitability Parameters

System Suitability test				
Analytes	RT(N=5)	Tailing Factor(N=5) Limit(NMT 2.0)	Theoretical Plates (N=5) Limit (NLT 2000)	%RSD (N=5) Limit (NMT 2.0)
Losartan potassium	11.85	1.1	19100	0.44
HCTZ	7.88	1.2	57200	0.47

Figure 1. Typical chromatogram of Losartan Potassium and Hydrochlorothiazide

CONCLUSION

Hence, the chromatographic method developed for Losartan Potassium and Hydrochlorothiazide were found to be simple, precise, accurate and cost effective and it can be effectively applied for routine analysis in

research institutions, quality control department in industries, approved testing laboratories, bio-pharmaceutical and bio-equivalence studies and in clinical pharmacokinetic studies in near future.

References

1. www.wikipedia.org/wiki/Losartan_Potassium
2. www.wikipedia.org/wiki/Hydrochlorothiazide
3. Ramana Rao G, Murthy SSN, Khadgapathi P. High performance liquid chromatography and its role in pharmaceutical analysis. *Eastern Pharmacist*, 29(346), 1986, 53.
4. Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC method development. 2nd ed. New York: Wiley InterScience; 1997, 1-57.
5. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. *J. Hypertension*, 13, 1995, S29-S33.
6. Lastra OC, Lemus IG, Sanchez HJ, Perez RF. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. *J Pharm Biomed Anal.*, 33, 2003, 175-80.
7. Zarakar SS and Kanyawar NS. Simultaneous estimation of Amlodipine and Losartan potassium in pharmaceutical dosage by RP-HPLC. *Indian drugs*, 39(6), 2002, 338-341.
8. Rao JR, et al. Methods of estimation of multicomponent formulations: a review. *Indian drugs*, 39(7), 2002, 378-381.
9. Deanne L Hertzog, et al. Developed and validated stability-indicating HPLC method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products. *Pharmacopoeial Forum*, 31(5), 2005, 1453-1463.
10. Wang ZY, Tain, Tain XL, Tain T. Simultaneous determination of Valsartan and Hydrochlorothiazide in tablets by RPHPLC. *Indian journal of pharmaceutical sciences*, 70(3), 2008, 372-374.
11. Shah NJ, Suhagia BN, Shah RR, Shah PB. Development and validation of a HPTLC method for the simultaneous estimation of telmisartan and hydrochlorothiazide in tablet. *Indian Journal of Pharmaceutical Sciences*, 69(2), 2007, 202-205.
12. Meyer VR. Practical high performance liquid chromatography. 2nd ed. New York: Wiley InterScience; 1994, 12.
13. PART 2: Validation of Analytical procedure: methodology Q2B, ICH Harmonized Tripartite Guidelines, 1996, 6-12.